Drug Trial Radar · NCT05732831
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
May 26, 2023
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Tango Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Conditions
- Locally Advanced Solid Tumor
Interventions
TNG462Drug
TNG462, a selective PRMT5 inhibitor, will be administered orally
PembrolizumabDrug
An anti PD-1 antibody, will be administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Maximum Tolerated DoseTime frame: 28 days and 21 days
- Phase 1 Dosing ScheduleTime frame: 28 days
- Phase 2 Anti-neoplastic ActivityTime frame: 16 weeks and 18 weeks
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California · Recruiting
Grand Valley Oncology
Grand Junction, Colorado · Recruiting
Florida Cancer Specialists & Research Institute
Lake Mary, Florida · Completed
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University Chicago Medicine
Chicago, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Midwestern Regional Medical Center, City of Hope Chicago
Zion, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Cancer Center
Detroit, Michigan · Recruiting
New York University Langone Health
New York, New York · Recruiting
Sarah Cannon Tennessee Oncology
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Next Oncology Virginia
Fairfax, Virginia · Recruiting
CHU de Brest
Brest, France · Recruiting
Centre Berard Leon
Lyon, France · Recruiting
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS
Saint-Herblain, France · Recruiting
Institute Gustav Roussy
Villejuif, France · Recruiting
Hospital HM Nou Delfos
Barcelona, Spain · Recruiting
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain · Recruiting
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
Hospital de Sanchinarro
Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Vall d'Hebron Barcelona Hospital
Barcelona, Catalonia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.